Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy. The main questions it aims to answer are: Does rivaroxaban reduce the incidence of venous thromboembolism (VTE) compared with aspirin in this patient population? What are the comparative safety profiles (particularly regarding bleeding events) of aspirin and rivaroxaban in this setting?
Epistemonikos ID: 9eed2753e9ae87432a158d7386c494867acc1d3c
First added on: Oct 31, 2026